Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works

A power primer.

Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771 · see citing works

Pathways towards and Away from Alzheimer’s Disease

Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052 · see citing works

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ ₄₂ in humans

Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · see citing works

PET imaging of amyloid deposition in patients with mild cognitive impairment

Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A. E., Ringheim, A., Långström, B., & Nordberg, A. K. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 725 · see citing works

Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M. N., Scheltens, P., Tariska, P., & Winblad, B. G. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 619 · see citing works

CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 604 · see citing works

Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice

Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573 · see citing works

Epidemiology and risk factors of dementia

van der Flier, W. M. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.082867 · Cited by 550 · see citing works

Relationships between biomarkers in aging and dementia

Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · see citing works

Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid

Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · see citing works

CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease

Westin, K., Buchhave, P., Nielsen, H., Minthon, L., Janciauskiene, S., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030525 · Cited by 277 · see citing works

Biological markers for therapeutic trials in Alzheimer’s disease

Frank, R., Galasko, D., Hampel, H. J., Hardy, J., de Leon, M. J., Mehta, P. D., Rogers, J., Siemers, E., & Trojanowski, J. Q. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00002-2 · Cited by 252 · see citing works

CSF levels of tau, β-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

Sjögren, M. J. C., Minthon, L., Davidsson, P., Granérus, A., Clarberg, A., Vanderstichele, H., Vanmechelen, E., Wallin, A., & Blennow, K. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070079 · Cited by 237 · see citing works

Fluid biomarkers in Alzheimer’s disease – current concepts

Rosén, C., Hansson, O., Blennow, K., & Zetterberg, H. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-20 · Cited by 214 · see citing works

Neurofilament protein in cerebrospinal fluid: A marker of white matter changes

Sjögren, M., Blomberg, M., Jonsson, M., Wahlund, L. ‐., Edman, Å., Lind, K., Rosengren, L., Blennow, K., & Wallin, A. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1242 · Cited by 209 · see citing works

Fluid Biomarkers in Alzheimer Disease

Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208 · see citing works

Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies

Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D’Amore, C., Pierguidi, L., Tambasco, N., Rossi, A., & Calabresi, P. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.016 · Cited by 173 · see citing works

Measurement of Thirteen Biological Markers in CSF of Patients with Alzheimer’s Disease and Other Dementias

Blasko, I., Lederer, W., OBERBAUER, H., Walch, T., Kemmler, G., Hinterhuber, H., Marksteiner, J., & Humpel, C. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000089137 · Cited by 170 · see citing works

Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

van Harten, A. C., Kester, M. I., Visser, P. J., Blankenstein, M. A., Pijnenburg, Y. A. L., van der Flier, W. M., & Scheltens, P. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.086 · Cited by 164 · see citing works

Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies

Kanemaru, K., Kameda, N., & Yamanouchi, H. (2000) · Neurology · doi:10.1212/wnl.54.9.1875 · Cited by 159 · see citing works

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 146 · see citing works

Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms

Sjögren, M. J. C., Davidsson, P., Wallin, A., Granérus, A., Grundström, E., Askmark, H., Vanmechelen, E., & Blennow, K. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000048642 · Cited by 145 · see citing works

Differential levels of -synuclein, -amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease

Kasuga, K., Tokutake, T., Ishikawa, A., Uchiyama, T., Tokuda, T., Onodera, O., Nishizawa, M., & Ikeuchi, T. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.197483 · Cited by 142 · see citing works

Rapid Progression from Mild Cognitive Impairment to Alzheimer’s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype

Blom, E. S., Giedraitis, V., Zetterberg, H., Fukumoto, H., Blennow, K., Hyman, B. T., Irizarry, M. C., Wahlund, L., Lannfelt, L., & Ingelsson, M. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000216841 · Cited by 141 · see citing works

The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia

Spies, P. E., Slats, D., Sjögren, M. J. C., Kremer, B. P. H., Verhey, F. R. J., Rikkert, M. G. M. O., & Verbeek, M. M. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383796 · Cited by 135 · see citing works

Core biological marker candidates of Alzheimer?s disease ? perspectives for diagnosis, prediction of outcome and reflection of biological activity

Hampel, H. J., Mitchell, A. J., Blennow, K., Frank, R., Brettschneider, S., Weller, L. J. R., & M�ller, H.-J. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0065-z · Cited by 132 · see citing works

Low frequency of post-lumbar puncture headache in demented patients

Blennow, K., Wallin, A., & Häger, O. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb04221.x · Cited by 130 · see citing works

Longitudinal changes of CSF biomarkers in memory clinic patients

Bouwman, F. H., van der Flier, W. M., Schoonenboom, N. S. M., van Elk, E. J., Kok, A., Rijmen, F., Blankenstein, M. A., & Scheltens, P. (2007) · Neurology · doi:10.1212/01.wnl.0000271375.37131.04 · Cited by 120 · see citing works

Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study

Sluimer, J. D., Bouwman, F. H., Vrenken, H., Blankenstein, M. A., Barkhof, F., van der Flier, W. M., & Scheltens, P. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.06.016 · Cited by 106 · see citing works

Altered CSF Orexin and α-Synuclein Levels in Dementia Patients

Wennström, M., Londos, E., Minthon, L., & Nielsen, H. M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111655 · Cited by 104 · see citing works

Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers

Parnetti, L., Lanari, A., Silvestrelli, G., Saggese, E., & Reboldi, G. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.022 · Cited by 101 · see citing works

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study

Tosun, D., Schuff, N. W., Truran‐Sacrey, D., Shaw, L. M. J., Trojanowski, J. Q., Aisen, P. S. S., Peterson, R., & Weiner, M. W. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.030 · Cited by 99 · see citing works

International quality control survey of neurochemical dementia diagnostics

Lewczuk, P., Beck, G., Ganslandt, O., Esselmann, H., Deisenhammer, F., Regeniter, A., Petereit, H.-F., Tumani, H., Gerritzen, A., Oschmann, P., et al. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.07.009 · Cited by 98 · see citing works

Cerebrospinal Fluid Amyloid ss42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia

de Jong, D., Jansen, R. W. M. M., Kremer, B. P. H., & Verbeek, M. M. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.7.755 · Cited by 98 · see citing works

Cerebrospinal Fluid Amyloid β1–42 Levels in the Mild Cognitive Impairment Stage of Alzheimer's Disease

Maruyama, M., Arai, H., Sugita, M., Tanji, H., Higuchi, M., Okamura, N., Matsui, T., Higuchi, S., Matsushita, S., Yoshida, H., et al. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7814 · Cited by 97 · see citing works

Cerebrospinal fluid tau, Aβ1–42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia

Jia, J., Meng, R., Sun, Y., Sun, W., Ji, X., & Jia, L. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.03.051 · Cited by 96 · see citing works

CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease

Perneczky, R., Tsolakidou, A. F., Arnold, A., Diehl‐Schmid, J., Grimmer, T., Förstl, H., Kurz, A., & Alexopoulos, P. (2011) · Neurology · doi:10.1212/wnl.0b013e318221ad47 · Cited by 94 · see citing works

Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration

Galimberti, D., Venturelli, E., Fenoglio, C., Guidi, I., Villa, C., Bergamaschini, L. C., Cortini, F., Scalabrini, D., Baron, P., Vergani, C., et al. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0737-6 · Cited by 94 · see citing works

CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease

Noguchi‐Shinohara, M., Tokuda, T., Yoshita, M., Kasai, T., Ono, K., Nakagawa, M., El‐Agnaf, O. M. A., & Yamada, M. (2008) · Brain Research · doi:10.1016/j.brainres.2008.11.055 · Cited by 92 · see citing works

Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment

Schott, J., Bartlett, J., Barnes, J., Leung, K. K., Ourselin, S., & Fox, N. C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.011 · Cited by 84 · see citing works

Cerebrospinal Fluid Abnormalities and Rate of Decline in Everyday Function Across the Dementia Spectrum

Okonkwo, O. C. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.118 · Cited by 76 · see citing works

Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease

Henneman, W. J. P., Vrenken, H., Barnes, J., Sluimer, I. C., Verwey, N. A., Blankenstein, M. A., Klein, M., Fox, N. C., Scheltens, P., Barkhof, F., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b879ac · Cited by 75 · see citing works

Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease

Prvulovic, D., & Hampel, H. J. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.087 · Cited by 73 · see citing works

Total tau protein, phosphorylated tau (181p) protein, β-amyloid1–42, and β-amyloid1–40 in cerebrospinal fluid of patients with dementia with Lewy bodies

Mollenhauer, B., Bibl, M., Wiltfang, J., Steinacker, P., Ciesielczyk, B., Neubert, K., Trenkwalder, C., & Otto, M. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.035 · Cited by 72 · see citing works

Preclinical AD Workgroup staging: Pathological correlates and potential challenges

Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71 · see citing works

Value of Neuropsychological Tests, Neuroimaging, and Biomarkers for Diagnosing Alzheimer's Disease in Younger and Older Age Cohorts

Schmand, B. A., Eikelenboom, P., van Gool, W. A., & Initiative, T. A. D. N. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03539.x · Cited by 69 · see citing works

Decreased sAβPPβ, Aβ 38 , and Aβ 40 Cerebrospinal Fluid Levels in Frontotemporal Dementia

Gabelle, A., Roche, S., Gény, C., Bennys, K., Labauge, P. M., Tholance, Y., Quadrio, I., Tiers, L., Gor, B., Boulanghien, J., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110515 · Cited by 67 · see citing works

Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample

Ibach, B., Binder, H., Dragon, M., Poljansky, S., Haen, E., Schmitz, E., Koch, H., Putzhammer, A., Kluenemann, H., Wieland, W. F., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.005 · Cited by 67 · see citing works

Neuropsychological and behavioural correlates of CSF biomarkers in dementia

Engelborghs, S., Maertens, K., Vloeberghs, E., Aerts, T., Somers, N., Mariën, P., & Deyn, P. P. D. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.11.002 · Cited by 67 · see citing works

Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease

Mouton‐Liger, F., Paquet, C., Dumurgier, J., Lapalus, P., Gray, F., Laplanche, J., & Hugon, J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.031 · Cited by 64 · see citing works

Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline

Nettiksimmons, J., Harvey, D. J., Brewer, J. B., Carmichael, O. T., DeCarli, C. S., Jack, C. R., Petersen, R. C., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.025 · Cited by 64 · see citing works

Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer

Petra, E. S. (2012) · Frontiers in bioscience · doi:10.2741/4035 · Cited by 62 · see citing works

Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study.

Wada-isoe, K., Kitayama, M., Nakaso, K., & Nakashima, K. (2007) · Journal of Neurological Sciences · doi:10.1016/j.jns.2007.03.016 · Cited by 54 · see citing works

CSF amyloid  38 as a novel diagnostic marker for dementia with Lewy bodies

Mulugeta, E., Londos, E., Ballard, C., Alves, G., Zetterberg, H., Blennow, K., Skogseth, R., Minthon, L., & Aarsland, D. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199398 · Cited by 54 · see citing works

The development of effective biomarkers for Alzheimer's disease: a review

Henry, M. S., Passmore, A. P., Todd, S., McGuinness, B., Craig, D., & Johnston, J. A. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3829 · Cited by 49 · see citing works

Computing Effect Size Measures with ViSta-The Visual Statistics System

Ledesma, R. D., Macbeth, G., & de Kohan, N. C. (2009) · Tutorials in Quantitative Methods for Psychology · doi:10.20982/tqmp.05.1.p025 · Cited by 47 · see citing works

Impact of SORL1 Single Nucleotide Polymorphisms on Alzheimer’s Disease Cerebrospinal Fluid Markers

Alexopoulos, P., Guo, L., Kratzer, M., Westerteicher, C., Kurz, A., Perneczky, R., & Initiative, A. D. N. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000332017 · Cited by 41 · see citing works

Additional Value of CSF Amyloid-β40 Levels in the Differentiation between FTLD and Control Subjects

Verwey, N. A., Kester, M. I., van der Flier, W. M., Veerhuis, R., Berkhof, J. H., Twaalfhoven, H. A. M., Blankenstein, M. A., Scheltens, P., & Pijnenburg, Y. A. L. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1392 · Cited by 34 · see citing works

Cystatin C Levels are Positively Correlated with both Aβ42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls

Sundelöf, J., Sundström, J., Hansson, O., Eriksdotter-Jönhagen, M., Giedraitis, V., Larsson, A., Degerman-Gunnarsson, M., Ingelsson, M., Minthon, L., Blennow, K., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091594 · Cited by 32 · see citing works

Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting

Lanari, A., & Parnetti, L. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.106 · Cited by 32 · see citing works

Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias

Herbert, M. K., Aerts, M. B., Kuiperij, H. B., Claassen, J. A. H. R., Spies, P. E., Esselink, R. A. J., Bloem, B. R., & Verbeek, M. M. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1775 · Cited by 28 · see citing works

SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer’s disease

Guo, L., Westerteicher, C., Wang, X., Kratzer, M., Tsolakidou, A. F., Jiang, M., Grimmer, T., Laws, S. M., Alexopoulos, P., Bujo, H., et al. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0295-x · Cited by 28 · see citing works

Cerebrospinal Fluid Neurochemical Phenotypes in Vascular Dementias: Original Data and Mini-Review

Bibl, M., Mollenhauer, B., Esselmann, H., Schneider, M., Lewczuk, P., Welge, V., Gross, M., Falkai, P., Kornhuber, J., & Wiltfang, J. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000115975 · Cited by 26 · see citing works

Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease

Habert, M., de Souza, L. C., Lamari, F., Daragon, N., Désarnaud, S., Jardel, C., Dubois, B., & Sarazin, M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1285-8 · Cited by 25 · see citing works

Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum

Solé‐Padullés, C., Lladó, A., Bartrés‐Faz, D., Fortea, J., Sánchez‐Valle, R., Bosch, B., Antonell, A., Molinuevo, J. L., & Rami, L. (2011) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2010.12.001 · Cited by 19 · see citing works

Tau-Proteins as Gender-Specific State Markers in Amnestic Mild Cognitive Impairment

Riepe, M., Karl, J., Tumani, H., & von Arnim, C. V. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318738 · Cited by 14 · see citing works

Glycemia and Levels of Cerebrospinal Fluid Amyloid and Tau in Patients Attending a Memory Clinic

Exalto, L. G., van der Flier, W. M., Scheltens, P., & Biessels, G. J. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02854.x · Cited by 13 · see citing works

Letter to the Editor: LOW SPECIFICITY LIMITS THE USE OF THE CEREBROSPINAL FLUID AB1-42/P-TAU181P RATIO TO DISCRIMINATE ALZHEIMER'S DISEASE FROM VASCULAR DEMENTIA

Bastard, N. L., Buggenhout, M. V., Leenheir, E. D., Martin, J., Deyn, P. P. D., & Engelborghs, S. (2007) · The Journals of Gerontology Series A · doi:10.1093/gerona/62.8.923 · Cited by 10 · see citing works

Untitled work

Price (1999) · doi:10.1002/1531-8249(199903)45:3

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994 · see citing works

Organ aging signatures in the plasma proteome track health and disease

Oh, H. S.-H., Rutledge, J., Nachun, D., Pálovics, R., Abiose, O., Moran-Losada, P., Channappa, D., Urey, D. Y., Kim, K., Sung, Y. J., et al. (2023) · Nature · doi:10.1038/s41586-023-06802-1 · Cited by 634 · see citing works

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramı́rez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 308 · see citing works

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia

Ismail, Z., Black, S. E., Camicioli, R., Chertkow, H., Herrmann, N., Laforce, R., Montero‐Odasso, M., Rockwood, K., Rosa‐Neto, P., Seitz, D., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12105 · Cited by 245 · see citing works

Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia

Skillbäck, T. B., Farahmand, B. Y., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A. B., Winblad, B. G., Schott, J. M., et al. (2015) · Brain · doi:10.1093/brain/awv181 · Cited by 215 · see citing works

FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort

Caminiti, S. P., Ballarini, T., Sala, A., Cerami, C., Presotto, L., Santangelo, R., Fallanca, F., Vanoli, E. G., Gianolli, L., Iannaccone, S., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.01.019 · Cited by 146 · see citing works

Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122 · see citing works

Aggregation of Disordered Proteins Associated with Neurodegeneration

Tsoi, P. S., Quan, M. D., Ferreon, J. C., & Ferreon, A. C. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043380 · Cited by 97 · see citing works

An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer’s Disease

Ratan, Y., Rajput, A., Maleysm, S., Pareek, A., Jain, V. K., Pareek, A., Kaur, R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051398 · Cited by 87 · see citing works

Amyloid-β and Astrocytes Interplay in Amyloid-β Related Disorders

Batarseh, Y. S., Duong, Q.-V., Mousa, Y. M., Rihani, S. B. A., Elfakhri, K. H., & Kaddoumi, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030338 · Cited by 80 · see citing works

Role of Withaferin A and Its Derivatives in the Management of Alzheimer’s Disease: Recent Trends and Future Perspectives

Das, R. C., Rauf, A., Akhter, S., Islam, M. N., Emran, T. B., Mitra, S., Khan, I. N., & Mubarak, M. S. (2021) · Molecules · doi:10.3390/molecules26123696 · Cited by 79 · see citing works

Sectoral segmentation of retinal amyloid imaging in subjects with cognitive decline

Dumitrascu, O. M., Lyden, P. D., Torbati, T., Sheyn, J., Sherzai, A. Z., Sherzai, D., Sherman, D. S., Rosenberry, R., Cheng, S. C., Johnson, K., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12109 · Cited by 60 · see citing works

Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors

Rivero‐Santana, A., Ferreira, D., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano-Aguilar, P. G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160366 · Cited by 56 · see citing works

Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer’s Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD

Hwang, J., Jeong, J. H., Yoon, S. J., Park, K. W., Kim, E., Yoon, B., Jang, J., Kim, H. J., Hong, J. Y., Lee, J., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030341 · Cited by 52 · see citing works

A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in Belgium

Somers, C., Struyfs, H., Goossens, J., Niemantsverdriet, E., Luyckx, J., Roeck, N. D., Roeck, E. E. D., Vil, B. B. D., Cras, P. P., Martin, J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151097 · Cited by 50 · see citing works

Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders

Wang, Z.-Y., Han, Z.-M., Liu, Q.-F., Tang, W., Ye, K., & Yao, Y.-Y. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000447 · Cited by 39 · see citing works

CSF biomarkers in neurodegenerative and vascular dementias

Llorens, F., Schmitz, M., Ferrer, I., & Zerr, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.003 · Cited by 39 · see citing works

New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia

Amin, S., Carling, G., & Gan, L. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.10.001 · Cited by 37 · see citing works

Role of insulin resistance in Alzheimer’s disease

Cai, Z., Xiao, M., Chang, L., & Yan, L. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9631-3 · Cited by 38 · see citing works

CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI “imminent” converters to AD

Santangelo, R., Masserini, F., Agosta, F., Sala, A., Caminiti, S. P., Cecchetti, G., Caso, F., Martinelli, V., Pinto, P., Passerini, G., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04853-4 · Cited by 37 · see citing works

Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer’s Disease and Cognitively Healthy People

de Oliveira, F. F., Miraldo, M. C., de Castro-Neto, E. F., de Almeida, S. S., Matas, S. L. D. A., Bertolucci, P. H. F., & Naffah‐Mazzacoratti, M. D. G. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210272 · Cited by 31 · see citing works

Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update

Oeckl, P., Steinacker, P., Feneberg, E., & Otto, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13669 · Cited by 30 · see citing works

Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease

Baldeiras, I., Santana, I. J., Leitão, M. J., Ribeiro, M. H., Pascoal, R., Duro, D., Lemos, R., Santiago, B., Almeida, M. R., & Oliveira, C. R. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.09.022 · Cited by 29 · see citing works

Biomarkers in Alzheimer’s, Frontotemporal, Lewy Body, and Vascular Dementias

Koenig, A. M., Nobuhara, C. K., Williams, V. J., & Arnold, S. E. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20170048 · Cited by 28 · see citing works

CSF placental growth factor – a novel candidate biomarker of frontotemporal dementia

Hansson, O., Santillo, A. F., Meeter, L. H. H., Nilsson, K. H., Waldö, M. L., Nilsson, C., Blennow, K., Swieten, J. C. V., & Janelidze, S. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.763 · Cited by 20 · see citing works

Diagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies

Bousiges, O., & Blanc, F. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.11.027 · Cited by 17 · see citing works

Selecting Aβ Isoforms for An Alzheimer’s Disease Cerebrospinal Fluid Biomarker Panel

Somers, C., Goossens, J., Engelborghs, S., & Bjerke, M. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0276 · Cited by 13 · see citing works

CSF Aβ1–42, but not p-Tau181, differentiates aMCI from SCI

Rizzi, L., Portal, M. M., Batista, C. E. A., Missiaggia, L., & Roriz‐Cruz, M. (2017) · Brain Research · doi:10.1016/j.brainres.2017.10.008 · Cited by 12 · see citing works

Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease

Vahid, Z. F., Eskandani, M., Dadashi, H., Vandghanooni, S., & Rashidi, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40756 · Cited by 12 · see citing works

Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects

Blanc, F., & Bousiges, O. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.008 · Cited by 8 · see citing works

CSF Aβ1–42, but not p-Tau181, Predicted Progression from Amnestic MCI to Alzheimer’s Disease Dementia

Rizzi, L., Missiaggia, L., & Roriz‐Cruz, M. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-018-8516-8 · Cited by 7 · see citing works

Cognitive impairment in Parkinson's disease.

Ransmayr, G. N. (2015) · PubMed · Cited by 5 · see citing works

Trace amounts of pyroglutaminated Aβ-(3–42) enhance aggregation of Aβ-(1–42) on neuronal membranes at physiological concentrations: FCS analysis of cell surface

Yano, Y., Takeno, A., & Matsuzaki, K. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.01.023 · Cited by 5 · see citing works

New perspectives in the search for reliable biomarkers in Alzheimer disease

Moreno‐Martínez, L., Osta, R., & Calvo, A. C. (2015) · The European Journal of Psychiatry · doi:10.4321/s0213-61632015000100005 · Cited by 3 · see citing works

Current and Developing Methods for Diagnosing Alzheimer's Disease

Fuller, S. J., Carrigan, N., Sohrabi, H. R., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch3 · Cited by 2 · see citing works

New Frontiers in Alzheimer's Disease Diagnosis

Llorens, F., Nuhn, S., Peter, C., Zerr, I., & Stoeck, K. (2015) · InTech eBooks · doi:10.5772/59652

Alpha-synuclein in cerebrospinal fluid

Tokuda, T., Ishii, R., Tatebe, H., Kasai, T., & el-Agnaf, O. (2017) · Springer eBooks · doi:10.1007/978-4-431-55948-1_13 · Cited by 2 · see citing works

Response to Dr. Finucane

Teng, E., & Mendez, M. F. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15234

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Bibl, M., Gallus, M., Welge, V., Esselmann, H., Wolf, S., Rüther, E., & Wiltfang, J. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0801-3 · Cited by 59 · see citing works

Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice

Parnetti, L., Lanari, A., Saggese, E., Spaccatini, C., & Gallai, V. (2003) · Neurological Sciences · doi:10.1007/s10072-003-0129-8 · Cited by 21 · see citing works

CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study

Ewers, M., Mattsson, N., Minthon, L., Molinuevo, J. L., Antonell, A., Popp, J., Jessen, F., Herukka, S., Soininen, H., Maetzler, W., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.12.006 · Cited by 133 · see citing works

Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment

Hansson, O., Zetterberg, H., Buchhave, P., Andréasson, U., Londos, E., Minthon, L., & Blennow, K. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000100926 · Cited by 286 · see citing works

Distinction between mild cognitive impairment and Alzheimer's disease by CSF amyloid β40 and β42, and protein-conjugated acrolein

Mizoi, M., Yoshida, M., Saiki, R., Waragai, M., Uemura, K., Akatsu, H., Kashiwagi, K., & Igarashi, K. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.007 · Cited by 36 · see citing works